Skip to main content
. Author manuscript; available in PMC: 2015 Feb 15.
Published in final edited form as: J Immunol. 2014 Jan 24;192(4):1693–1706. doi: 10.4049/jimmunol.1302511

Table 1. Summary of MPER+ serum Ab responses in C57BL/6 & BALB/c mice immunized with various adjuvant + HIV-1 Envelope protein/MPER peptide combinations.

Immunization Regimen MPER+ (2F5 nominal epitope-specific) serum Ig endpoint titer ranges1
Route Prime Boosts (x4) C57BL/6 (H-2b) BALB/c (H-2d)
IM oCpG oCpG - -
IP oCpG oCpG - -
IM Env (CONS)2+RIBI3 Env (CON-S) + RIBI - -
IP Env (CONS) + RIBI Env (CON-S) + RIBI - -
IM Env (CONS) +oCpG Env (CON-S) + oCpG - +
IP Env (CONS) +oCpG Env (CON-S) + oCpG - +
IP Env (CONS) +oCpG Env (CON-S) + oCpG - ++
IM DP178Q16L4 + RIBI DP178Q16L + RIBI - ++
IP DP178Q16L + RIBI DP178Q16L + RIBI - ++
IP Env (JRFL) + Alum CGG-DP178Q16L + Alum - ++ → +++
IP Env (JRFL) + oCpG CGG-DP178Q16L + oCpG - +++
IP GTH1-MPER 6564 + oCpG/MPLA GTH1MPER 656 + oCpG/MPLA - ++ → +++
IM Env (JRFL) + oCpG GTH1-MPER 656 + oCpG/MPLA - ++ → +++
IP Env (JRFL) + oCpG GTH1-MPER 656 + oCpG/MPLA - → +/- ++++
IM Env (JRFL) + oCpG Liposomes5 (with GTH1-MPER 656/MPLA) + oCpG - → +/- +++ → +++++
IP Env (JRFL)+oCpG Liposomes (with GTH1-MPER 656/MPLA) + oCpG - → +/- +++++
1

Reciprocal endpoint titer averages of immunization groups (≥4 mice/group) were calculated as previously described (28). Symbols denote the magnitude of Ab responses at peak induction (5th immunizations) as follows: (-) = <102, (-/+) = 102-103, (+) = 103-104, (++) = 104-105, (+++) = 105-106, (++++) = 106-107, (+++++) = >107. Where applicable, arrows denote the observed range across two independent experiments. Data specifically shown for the JRFL prime+MPER liposome boosts (the regimen predominantly used throughout this manuscript) is based on four independent experiments.

2

Env = recombinant gp140 Envelope Consensus (CON-S) or JRFL proteins (37,81).

3

RIBI and oCpG adjuvants were formulated in 10% Oil/water Emulsigen (MVP technologies), as previously described (37,78).

4

MPER peptides DP178Q16L and GTH1-656 MPER have been previously described (36,44,78).

5

Liposome-MPER peptide conjugate immunogens, were prepared based on previous methodologies (36,38) and as further described in the Materials and Methods section.